Physician profile
Angelyn Danowski
NPI 1902635840
$1,015.91
in general payments reported to CMS, 2019-2025
12 companies · $900 in 2025
The $900 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $116 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,003 · Education: $13.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,002.74 |
| Education | $13.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $231.61 | 2024-2025 | |
| Janssen Biotech, INC. | $216.68 | 2024-2025 | Tremfya |
| Genzyme Corporation | $192.31 | 2024-2025 | |
| Amgen INC. | $85.14 | 2024-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $69.41 | 2025 | Libtayo, Dupixent |
| Incyte Corporation | $51.49 | 2025 | Opzelura |
| Ucb, INC. | $49.72 | 2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.38 | 2025 | Spevigo |
| Organon LLC | $31.15 | 2025 | |
| Leo Pharma INC. | $25.58 | 2025 | Anzupgo |
| Lilly USA, LLC | $17.27 | 2025 | Ebglyss |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angelyn Danowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.